Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B; Swiss HIV Cohort Study. Fagard C, et al. Among authors: mclean a. Arch Intern Med. 2003 May 26;163(10):1220-6. doi: 10.1001/archinte.163.10.1220. Arch Intern Med. 2003. PMID: 12767960 Free article.
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE. Oxenius A, et al. Among authors: mclean a. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52. doi: 10.1073/pnas.202372199. Epub 2002 Oct 7. Proc Natl Acad Sci U S A. 2002. PMID: 12370434 Free PMC article. Clinical Trial.
Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.
Oxenius A, McLean AR, Fischer M, Price DA, Dawson SJ, Hafner R, Schneider C, Joller H, Hirschel B, Phillips RE, Weber R, Günthard HF; Swiss HIV Cohort Study Group. Oxenius A, et al. Among authors: mclean ar. J Virol. 2002 Oct;76(20):10169-76. doi: 10.1128/jvi.76.20.10169-10176.2002. J Virol. 2002. PMID: 12239291 Free PMC article.
Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS.
Scherer A, Frater J, Oxenius A, Agudelo J, Price DA, Günthard HF, Barnardo M, Perrin L, Hirschel B, Phillips RE, McLean AR; Swiss HIV Cohort Study. Scherer A, et al. Among authors: mclean ar. Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12266-70. doi: 10.1073/pnas.0404091101. Epub 2004 Aug 9. Proc Natl Acad Sci U S A. 2004. PMID: 15302942 Free PMC article.
Mapping the drivers of within-host pathogen evolution using massive data sets.
Palmer DS, Turner I, Fidler S, Frater J, Goedhals D, Goulder P, Huang KG, Oxenius A, Phillips R, Shapiro R, Vuuren CV, McLean AR, McVean G. Palmer DS, et al. Among authors: mclean ar. Nat Commun. 2019 Jul 9;10(1):3017. doi: 10.1038/s41467-019-10724-w. Nat Commun. 2019. PMID: 31289267 Free PMC article.
HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection.
Duda A, Lee-Turner L, Fox J, Robinson N, Dustan S, Kaye S, Fryer H, Carrington M, McClure M, McLean AR, Fidler S, Weber J, Phillips RE, Frater AJ; SPARTAC Trial Investigators. Duda A, et al. Among authors: mclean ar. J Virol. 2009 Feb;83(3):1228-39. doi: 10.1128/JVI.01545-08. Epub 2008 Nov 19. J Virol. 2009. PMID: 19019964 Free PMC article.
1,600 results